Abstract
609 Background: Controversy still exists about adjuvant treatment decision for small node negative (N0) early breast cancer (BC). Retrospective evaluations of clinical and pathological data show different outcomes. The objective of our analysis is to evaluate recurrence risk in patients (pts) with pT1abc, N0 BC accordingly with some prognostic biological factors. Methods: We retrospectively evaluated 600 pts who underwent surgery between 2000 and 2009 in 4 italian oncologic centers. Survival analysis was performed only for pts enrolled until December 2007 (563 pts) in order to obtain a minimum follow up (FU) of 3 years (yr). Results: Median age at diagnosis 59 (range 21-86); premenopausal 28%; invasive ductal carcinoma 89%; Ki 67>15% 51%; histologic grade (G)1 17%, G2 50%, G3 18%, no data in 15% of pts; pT1a 8%; pT1b 37%; pT1c 55%. We defined 3 cohorts: ER positive (ER+) 82%; HER2 overexpressed or amplified (HER2+) 10%; triple negative (TN) 8%. All ER+ pts received adjuvant hormonal treatment. Chemotherap...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
